$Low molecular weight fucoidan fraction LF2 improves metabolic syndrome via up-regulating PI3K-AKT-mTOR axis and increasing the abundance of Akkermansia muciniphila in the gut microbiota$

Low molecular weight fucoidan fraction LF2 improves metabolic syndrome via up-regulating PI3K-AKT-mTOR axis and increasing the abundance of Akkermansia muciniphila in the gut microbiota

Metabolic syndrome (MetS) is a pathological condition of a variety of metabolic abnormalities, which requires more urgent treatment and intervention. Fucoidan has been recommended as a supplement for health enhancement and disease management. Here, we first propose that the beneficial effect of low...

Full description

Bibliographic Details
Main Authors:	Deng, Z. (Author), Geng, L. (Author), Wang, F. (Author), Wang, J. (Author), Wu, N. (Author), Yue, Y. (Author), Zhang, Q. (Author)
Format:	Article
Language:	English
Published:	Elsevier B.V. 2021
Subjects:	Akkermansia animal Animals C57BL mouse drug effect Fucoidan fucoidin Gastrointestinal Microbiome Gut microbiota homeostasis Homeostasis inflammation Inflammation insulin resistance Insulin Resistance intestine flora male Male Metabolic syndrome Metabolic Syndrome metabolic syndrome X Mice Mice, Inbred C57BL mouse polysaccharide Polysaccharides
Online Access:	View Fulltext in Publisher

Internet

View Fulltext in Publisher

Low molecular weight fucoidan fraction LF2 improves metabolic syndrome via up-regulating PI3K-AKT-mTOR axis and increasing the abundance of Akkermansia muciniphila in the gut microbiota

Internet

Similar Items